The U.S. Food and Drug Administration has approved Priovant Therapeutics’ LISRAYA, or brepocitinib, for adults with dermatomyositis, creating the first FDA-approved oral treatment for the rare systemic autoimmune disease. The decision converts positive Phase 3 VALOR data into Roivant Sciences’ first commercial opportunity for a drug that is also being developed across several other immune-mediated
TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.
Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.
Injectable safety is becoming a workflow battle. Avenacy’s tranexamic acid launch tests demand for ready-to-use hospital formats.
Bristol Myers Squibb and Pfizer have brought Eliquis, the oral anticoagulant apixaban, into a new direct access channel through Mark Cuban Cost Plus Drug Company, making the medicine available to cash-paying patients in the United States from April 27, 2026. The move places one of the country’s most widely prescribed branded blood thinners inside a
Eliquis faces pricing pressure, but Bristol Myers Squibb and Pfizer are moving first. Direct access may become pharma’s new defence.
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.
Flagship Pioneering has launched a new research program with Pfizer through its portfolio company Repertoire Immune Medicines, focused on the development of T cell receptor (TCR) bispecifics for metastatic prostate cancer. This marks the eighth initiative under the broader Flagship–Pfizer strategic alliance. The program will harness Repertoire’s DECODE platform to map immune synapse interactions and